Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SymBio Pharmaceuticals's total inventories for the quarter that ended in Jun. 2026 was 円150 Mil. SymBio Pharmaceuticals's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was 円167 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. SymBio Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was 円-17.36.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
SymBio Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SymBio Pharmaceuticals (TSE:4582) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
SymBio Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
SymBio Pharmaceuticals's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
SymBio Pharmaceuticals Total Inventories Related Terms
SymBio Pharmaceuticals Total Inventories Historical Data
* Premium members only.
The historical data trend for SymBio Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
SymBio Pharmaceuticals (TSE:4582) has a Total Inventories of 円150 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Total Inventories too high?
SymBio Pharmaceuticals' current Total Inventories is 円150 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Total Inventories compare to ZTS?
SymBio Pharmaceuticals' Total Inventories of 円150 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Total Inventories is 円150 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Significantly Overvalued. The stock's GF Value™ is 円43.47, compared to a current price of 円64.00 — trading 47.2% above its estimated fair value. The current Total Inventories is 円150 Mil. SymBio Pharmaceuticals' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Total Inventories is 円150 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of 円64.00 is trading 47.2% above its estimated GF Value™ of 円43.47.
GuruFocus considers SymBio Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSE:4582:
Total Inventories: 円150 Mil
GF Value™: 円43.47 vs. price of 円64.00 (47.2% above fair value)
No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
27GF Score
Get the complete analysis for TSE:4582
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4582 has been successfully added to your 
